MMCB investing ₽15 million in Orfagenex, a biotechnology startup developing gene therapies for the treatment of rare (orphan) neuromuscular diseases, including spinal muscular atrophy (SMA). So far, ₽10.5 million has been provided. Remaining funds will be allocated by the end of 2026. Funds will be used for preclinical development, scaling up the production...

MMCC has placed 1,217 remaining shares of the additional issue, which were not redeemed under the pre-emptive right, for an OTC placement. The price of the securities is set at ₽116 per share.

The Moscow Exchange has set a price target for preliminary applications for the SPO of Gemabank at 116 ₽ per share. Applications will be accepted from June 15 to June 18, inclusive.

MMCB has successfully completed in vitro (in vitro) laboratory tests of a range of new gene therapy drugs for the treatment of hemophilia A and B. Now the company's specialists have launched a testing phase on mice in order to determine the minimum effective dose of the drug. The hemophilia therapy market remains one of the largest segments of orphan disease...